Fibrometabolism modulator - Lmito Therapeutics
Latest Information Update: 03 Feb 2023
At a glance
- Originator Lmito Therapeutics
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Dec 2022 Early research in Idiopathic pulmonary fibrosis in South Korea (unspecified route) (Lmito Therapeutics pipeline, December 2022)